---
title: Telecoaching to Improve Physical Activity in Patients With Obstructive Sleep Apnea
nct_id: NCT03205878
overall_status: UNKNOWN
phase: NA
sponsor: Universitaire Ziekenhuizen KU Leuven
study_type: INTERVENTIONAL
primary_condition: Physical Activity
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03205878.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03205878"
ct_last_update_post_date: 2017-07-02
last_seen_at: "2026-05-12T07:33:48.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Telecoaching to Improve Physical Activity in Patients With Obstructive Sleep Apnea

**Official Title:** Improving Physical Activity in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure

**NCT ID:** [NCT03205878](https://clinicaltrials.gov/study/NCT03205878)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 102
- **Lead Sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Conditions:** Physical Activity, Obstructive Sleep Apnea
- **Start Date:** 2017-07-01
- **Completion Date:** 2019-12-31
- **CT.gov Last Update:** 2017-07-02

## Brief Summary

Patients with obstructive sleep apnea (OSA) are less physically active than healthy controls.

First choice of treatment for OSA is continuous positive airway pressure (CPAP) therapy with an improvement in oxygen saturation and sleep. No improvement on physical activity has been shown.

The current study would randomize patients in a standard care group (CPAP) and an intervention group (CPAP + telecoaching). Telecoaching will be performed for 3 months, with physical activity assessment before, after 3 months and 12 years.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* AHI \> 15 events/hour, measured by polysomnography
* \< 7,500 steps per day
* Willing to start CPAP treatment
* Age between 18 and 65 years
* Signing the written informed consent

Exclusion Criteria:

* Patients with neuromuscular diseases
* Patients with chronic obstructive pulmonary disease and interstitial lung disease
* Patients with cardiac failure and ischemic heart failure
* Patients with comorbidities which could interfere with a normal biomechanical gait pattern and the possibility of increasing physical activity
* Patients with mental disability making it impossible to understand the study protocol and the use of electronic devices.
```

## Arms

- **Control group** (ACTIVE_COMPARATOR) — Patients will receive standard care, being CPAP treatment
- **Intervention group** (EXPERIMENTAL) — Patients will receive CPAP and telecoaching

## Interventions

- **Telecoaching** (OTHER) — Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.

Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set.
- **CPAP** (DEVICE) — Patients will receive CPAP according to standard care

## Primary Outcomes

- **Change in steps per day after 3 months** _(time frame: The change will be measured after 3 months)_ — Steps per day as measured by a step counter

## Secondary Outcomes

- **The proportion of patients with an increase > 1,000 steps per day** _(time frame: After 3 months (end of telecoaching) and after 12 months)_
- **The proportion of patients with > 7500 steps/day** _(time frame: Before initiation of telecoaching (baseline), after 3 months (end of telecoaching) and after 12 months)_
- **Change in functional exercise capacity** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in daytime sleepiness** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in sleep quality** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in endothelial function** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in body composition** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in quality of life** _(time frame: 3 months and 12 months compared with baseline)_
- **Change in steps per day after 12 months** _(time frame: The change will be measured after 12 months)_

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03205878.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03205878*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*